K
Kristen McEachern
Researcher at AstraZeneca
Publications - 21
Citations - 1065
Kristen McEachern is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer research & Immune system. The author has an hindex of 7, co-authored 14 publications receiving 866 citations.
Papers
More filters
Journal ArticleDOI
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Michael Hedvat,Dennis Huszar,Andreas Herrmann,Joseph M. Gozgit,Anne Schroeder,Adam Sheehy,Ralf Buettner,David Proia,Claudia M. Kowolik,Hong Xin,Brian Armstrong,Geraldine Bebernitz,Shaobu Weng,Lin Wang,Minwei Ye,Kristen McEachern,Huawei Chen,Deborah Morosini,Kirsten Bell,Marat Alimzhanov,Stephanos Ioannidis,Patricia McCoon,Zhu A. Cao,Hua Yu,Richard Jove,Michael Zinda +25 more
TL;DR: The essential role of Stat3 downstream of Jaks is demonstrated by inhibition of tumor growth using short hairpin RNA targeting Stat3, supporting a key role of Jak kinase activity in Stat3-dependent tumorigenesis.
Journal ArticleDOI
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
Erika Krasnickas Keeton,Kristen McEachern,Keith Dillman,Sangeetha Palakurthi,Yichen Cao,Michael Grondine,Surinder Kaur,Surinder Kaur,Suping Wang,Yuching Chen,Allan Wu,Minhui Shen,Francis D. Gibbons,Michelle Lamb,Xiaolan Zheng,Richard Stone,Daniel J. DeAngelo,Leonidas C. Platanias,Leonidas C. Platanias,Les A. Dakin,Huawei Chen,Paul Lyne,Dennis Huszar +22 more
TL;DR: AZD1208 inhibits the growth of MOLM-16 and KG-1a xenograft tumors in vivo with a clear pharmacodynamic-pharmacokinetic relationship and underscores the therapeutic potential of Pim kinase inhibition for the treatment of AML.
Journal ArticleDOI
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
Ila Datar,Ila Datar,Miguel F. Sanmamed,Miguel F. Sanmamed,Jun Wang,Brian S. Henick,Brian S. Henick,Jungmin Choi,Ti Badri,Weilai Dong,Nikita Mani,Maria I. Toki,Luis Mejías,Maria D. Lozano,Jose Luis Perez-Gracia,Vamsidhar Velcheti,Matthew D. Hellmann,Matthew D. Hellmann,Justin F. Gainor,Kristen McEachern,David Jenkins,Konstantinos N. Syrigos,Katerina Politi,Katerina Politi,Scott N. Gettinger,David L. Rimm,David L. Rimm,Roy S. Herbst,Ignacio Melero,Lieping Chen,Kurt A. Schalper,Kurt A. Schalper +31 more
TL;DR: In baseline samples from 90 patients with advanced NSCLC treated with PD-1 axis blockers, elevated LAG-3 was significantly associated with shorter progression-free survival, suggesting independence of these immune evasion pathways.
Journal ArticleDOI
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.
Jorge E. Cortes,Kenji Tamura.,Daniel J. DeAngelo,Johann S. de Bono,David Lorente,Mark D. Minden,Geoffrey L. Uy,Hagop M. Kantarjian,Lisa S. Chen,Varsha Gandhi,Robert Godin,Karen Keating,Kristen McEachern,Karthick Vishwanathan,Janet Elizabeth Pease,Emma Dean +15 more
TL;DR: Despite the lack of single-agent clinical efficacy with AZD1208, PIM kinase inhibition may hold potential as an anticancer treatment, perhaps in combination with other agents.
Journal ArticleDOI
The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and Signaling
Bo Cen,Ying Xiong,Jin H. Song,Sandeep Mahajan,Rachel DuPont,Kristen McEachern,Daniel J. DeAngelo,Jorge E. Cortes,Mark D. Minden,Allen J. Ebens,Alice S. Mims,Amanda C. LaRue,Amanda C. LaRue,Andrew S. Kraft +13 more
TL;DR: A previously unrecognized mechanism that promotes MET expression in multiple tumor cell types is described and it is found that Pim-1 kinase activity regulates HGF-induced tumor cell migration, invasion, and cell scattering.